James Mackay

James Mackay has over 30 years of experience in the development of pharmaceuticals, and a strong record of bringing multiple drugs to market and patients. He is currently the founder, president, and CEO of Aristea Therapeutics. Previously, James served as the President and CEO of Ardea Biosciences, where he led the successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca. He held a number of senior roles in AstraZeneca’s Clinical Development Function as well as Global Product Vice President for Diabetes. James is currently chairof CONNECT (www.connect.org) Board of Directors and sits on the Board of Governors of Biocom. James is also an independent Board Director for Privo Technologies and Arthrosi Therapeutics. James holds a BSc in Genetics and a PhD in Medical Genetics from Aberdeen University, Scotland.